MabCampath (alemtuzumab)-Important Safety Information from Bayer HealthCare as approved by the IMB
11 February 2008
Please find herewith an important safety communicatin from Bayer on six infection-related deaths reported after treatment with MabCampath(alemtuzumab) following Fludarabine+Rituximab inductions in patients with B-Cell Chronic Lymphocytic Leukemia (CLL).